Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 10/20 | 0.40 |
| ▸ | SSTR2 | P30874 | 8/20 | 0.40 |
| ▸ | SSTR1 | P30872 | 7/20 | 0.40 |
| ▸ | SSTR3 | P32745 | 7/20 | 0.40 |
| ▸ | SSTR5 | P35346 | 6/20 | 0.40 |
| ▸ | TACR1 | P25103 | 2/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | GJB2 | P29033 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.30 |
| ▸ | CDC25B | P30305 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21080961 | 0.89 | SSTR1 (0.43) | SSTR4SSTR2SSTR1SSTR3SSTR5 | |
| SCHEMBL21080969 | 0.87 | LGALS3 (0.35) | SSTR4SSTR2SSTR1SSTR3SSTR5 | |
| SCHEMBL21080964 | 0.86 | SSTR1 (0.46) | SSTR4SSTR2SSTR1SSTR3SSTR5 | |
| SCHEMBL11886551 | 0.84 | SSTR1 (0.40) | SSTR4SSTR2SSTR1SSTR3SSTR5 | |
| SCHEMBL18333049 | 0.81 | GJB2 (0.45) | SSTR4SSTR2SSTR1SSTR3SSTR5 | |
| SCHEMBL16374731 | 0.81 | GJB2 (0.45) | SSTR4SSTR2SSTR1SSTR3SSTR5 | |
| SCHEMBL14670875 | 0.81 | GJB2 (0.45) | SSTR4SSTR2SSTR1SSTR3SSTR5 | |
| SCHEMBL18332876 | 0.81 | GJB2 (0.45) | SSTR4SSTR2SSTR1SSTR3SSTR5 | |
| SCHEMBL14579985 | 0.80 | SSTR1 (0.34) | SSTR4SSTR2SSTR1SSTR3SSTR5 | |
| SCHEMBL18681741 | 0.80 | SSTR1 (0.34) | SSTR4SSTR2SSTR1SSTR3SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336966-B2 | Fragrance compositions and uses thereof | THE PROCTER & GAMBLE COMPANY (US) | 2019-07-02 | — | — | US | claimed |
| EP-3103523-B1 | ABSORBENT ARTICLE COMPRISING FRAGRANCE COMPOSITION | PROCTER & GAMBLE (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-3141239-B1 | FRAGRANCE COMPOSITIONS AND USES THEREOF | PROCTER & GAMBLE (US) | 2023-05-10 | — | — | EP | disclosed |
| US-20210393506-A1 | FRAGRANCE BLENDS AND METHODS FOR PREPARATION THEREOF | JPMORGAN CHASE BANK, N.A. | 2021-12-23 | — | — | US | disclosed |
| EP-3103523-A1 | ABSORBENT ARTICLE COMPRISING FRAGRANCE COMPOSITION | The Procter and Gamble Company (US) | 2016-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336966-B2 | Fragrance compositions and uses thereof | CUTA, DPM1, PLIN5 | SSTR4 2912/4885SSTR2 3034/4885SSTR1 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.